FAP immunosuppressive CAR-DC

Phase 1Biologic

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

FAP immunosuppressive CAR-DC is one of 47 biologic programs targeting Acute Myocardial Infarction. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Myocardial InfarctionNot yet recruiting

Dilated Cardiomyopathy (DCM)Recruiting

Acute Myocardial InfarctionPhase 1

Not yet recruiting

Dilated Cardiomyopathy (DCM)Phase 1

Recruiting

Competition

Competitive Landscape

75 competitors in Acute Myocardial Infarction

#DrugCompanyPhaseTrials

Brilinta

AstraZeneca

Approved

8 2

Repatha

Amgen

Approved

3 3

Bayer Aspirin

Bayer

Approved

2 4

Eliquis

Bristol-Myers Squibb

Approved

1 5

Praluent

Regeneron

Approved

1 6

Onglyza

Neoral

Zebeta

Leqvio

Januvia

ZZydus Therapeutics Inc.

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Not yet recruiting

Acute Myocardial Infarction

NCT07380659

Q4 2027

Phase 1Recruiting

Dilated Cardiomyopathy (DCM)

NCT07516288

Q4 2028

PreclinicalRecruiting

Dilated Cardiomyopathy (DCM)

NCT06902896

Clinical

Trials by Indication[1]

Dilated Cardiomyopathy (DCM)2 trials

Safety and Efficacy of Immunosuppressive CAR-DC Targeting FAP in the Treatment of End-stage Dilated Cardiomyopathy

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Preclinical·NCT06902896·43 enrolled

Safety and Efficacy of Second Infusion of Autologous Immunosuppressive CAR-DC Targeting FAP in the Treatment of End-stage Dilated Cardiomyopathy

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT07516288·5 enrolled

Acute Myocardial Infarction1 trial

Safety and Efficacy of FAP iCDC in Acute Myocardial Infarction With Cardiogenic Shock

Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT07380659·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for FAP immunosuppressive CAR-DC. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FAP immunosuppressive CAR-DC compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FAP immunosuppressive CAR-DC. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Second Affiliated Hospital, School of Medicine, Zhejiang University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: SSecond Affiliated Hospital, School of Medicine, Zhejiang University

FAP immunosuppressive CAR-DC

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2027

Q4 2028

Trials by Indication[1]

Dilated Cardiomyopathy (DCM)2 trials

Acute Myocardial Infarction1 trial

References

Drug Info

Quick Facts

Related News